Journal
PHYTOTHERAPY RESEARCH
Volume 32, Issue 3, Pages 452-458Publisher
WILEY
DOI: 10.1002/ptr.5988
Keywords
osteoclast; Porphyra yezoensis; porphyran; RANKL; RAW264; 7 cells
Categories
Funding
- Japan Society for the Promotion of Science (JSPS) [14J00356]
- Nagasaki University Major Research Project (Research Initiative for Adaptation to Future Ocean Change)
- National Research Foundation of Korea [NRF-2017R1A2B4005582]
- Korea Basic Science Institute [C37230]
- Ministry of Education, Culture, Sports, Science and Technology of Japan [15K07580]
Ask authors/readers for more resources
Safe and efficient therapeutic agents for bone diseases are required in natural sources. We previously found that edible seaweed-derived polysaccharide porphyran exhibited anti-inflammatory effects through the down regulation of nuclear factor-B. The aim of this study was to investigate the availability of porphyran as a therapeutic agent for bone diseases. The effects of porphyran on receptor activator of nuclear factor B ligand (RANKL)-induced osteoclastogenesis in RAW264.7 cells were examined. Porphyran suppressed RANKL-induced osteoclast formation in a concentration-dependent manner (6.25-50g/ml) without any cytotoxic effects. Furthermore, real-time polymerase chain reaction analyses indicated that porphyran at 50g/ml significantly attenuated the RANKL-induced increase in the mRNA levels of osteoclastogenesis-related marker genes such as nuclear factor of activated T cells, tartrate-resistant acid phosphatase, cathepsin K, and matrix metalloproteinase-9 in RAW264.7 cells. To our knowledge, this is the first report showing that edible-seaweed-derived polysaccharide porphyran can suppress RANKL-induced osteoclastogenesis. Our results suggest that porphyran can be used as a safe therapeutic agent to improve osteoclast-related pathological conditions.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available